Characteristic |
Age in years, n (%) |
18–25 | 5 (11) | 34 (74) | | 2.72* (0.41 to 18.10) |
26–32 | 2 (4) | 5 (11) | | |
Median age (range) | 21 (18–31) | 21 (18–27) | 0.96† | |
Days from onset to hospital admission, n (%) |
0–3 | 1 (2) | 29 (63) | | 0.09‡ (0.01 to 0.68) |
4–7 | 6 (13) | 10 (22) | | |
Median days (range) | 4 (2–7) | 2 (0–7) | 0.004† | |
Antivirus use |
Days from onset to first dose of antiviral therapy, n (%) | | | | 0.06‡ (0.01 to 0.41) |
0–3 | 1 (2) | 32 (70) | | |
4–8 | 6 (13) | 7 (15) | | |
Median days (range) | 5 (2–8) | 3 (0–7) | 0.0054§ | |
Days of antiviral therapy | | | | 0.95* (0.21 to 4.30) |
1–3 | 2 (4) | 11 (24) | | |
3–11 | 5 (11) | 26 (57) | | |
Median days (range) | 5 (1–11) | 5 (2–11) | 0.32‡ | |
Hormone |
Days from onset to hormone use, n (%) | | | | 0.25‡ (0.03 to 1.86) |
1–3 | 1 (4) | 11 (41) | | |
4–9 | 5 (19) | 10 (38) | | |
Median days (range) | 5 (1–9) | 3 (0–9) | 0.056§ | |